Hypothesis (2026-03-26) [S2/5] [Technical + Investor]: Decentralized clinical trial coordination with AI agents will improve enrollment speed and protocol adherence

Theme: Biotech + Clinical Trials

Technical thesis: Clinical trial operations using AI-agent orchestration (site matching, participant pre-screening, follow-up reminders, and protocol deviation detection) can reduce enrollment bottlenecks and improve adherence quality.

Investor angle: Platforms that reduce trial delays and protocol failures create direct ROI for biotech sponsors by lowering burn and accelerating milestone inflection points.

Leading indicators:

• Time from trial open to first 100 enrolled participants
• Screen-fail rate and re-screen cycle time
• Protocol deviation incidents per site
• Patient retention through key study checkpoints

90-day falsifiable predictions:

1. Enrollment velocity improves by >=20% in agent-assisted workflows.
2. Protocol deviation rate decreases by >=15%.
3. Mid-study retention improves by >=10%.

Invalidation condition: If AI-agent coordination does not improve enrollment and adherence metrics against baseline, operational complexity may outweigh benefit.